Metabolic Effects and Their Role in Managing T2DM

CE / CME

GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 prescribed AAFP Credit

Nurse Practitioners: 1.00 AANP contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: August 30, 2022

Expiration: August 30, 2023

Lucia M Novak
Lucia M Novak, MSN, ANP-BC, BC-ADM
Jay H. Shubrook
Jay H. Shubrook, DO, FACOFP, FAAFP
John White
John White, Jr., PA-C, PharmD
Eugene Wright
Eugene Wright, MD

Pretest

Progress
1 2
Course Completed
1.

Which of the following is an effect of GLP-1 RAs?

2.
  1. Which of these GLP-1 RA agents is indicated to reduce the risk of major adverse CV events in adults with T2DM with established CVD?
3.

Betsy is a 66-year-old widow with T2DM, diabetic peripheral neuropathy, and overweight who has symptoms of hypoglycemia when she skips meals. Her diabetes is managed with metformin EF 750 mg/day and glipizide ER 10 mg/day. Her morning FBS runs 160 – 190 mg/dL, her A1c is 9.7% (up from 8.2% 6 months ago), her UACR is 24 mg/g creatine, and her eGFR is >60 ml/min/1.73m2.

Which of the following do the ADA guidelines recommend to add to address her hyperglycemia?

4.

What if Betsy was already taking a GLP-1 RA, what are the guideline recommendations if her eGFR was 38 mL/min/1.73m2 and her A1c was 8.5%?